Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Composición farmacéutica para el tratamiento del dolor y la fibromialgia

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150804003
Publicado:
21/08/2015
Caducidad:
20/08/2016
Resumen:
Un grupo español de investigación médica ha desarrollado una composición farmacéutica para el tratamiento efectivo del dolor en general y de la fibromialgia en particular. Esta composición incorpora ketamina y pregabalina, análogos de ácidos, arilcicloalquilaminas aminobutíricas y ciclidinas estructuralmente relacionadas. La composición se administra por vía intravenosa y ha sido probada en 36 pacientes. Se buscan socios de la industria farmacéutica con el fin de establecer acuerdos de licencia.

Details

Tittle:
Pharmaceutical composition used to treat pain and for the treatment of Fibromyalgia
Summary:
A Spanish medical research group has developed a pharmaceutical composition for the effective treatment of pain in general and particularly for the treatment of Fibromyalgia.
Partners from the pharmaceutical industry are sought for licensing agreements.
Description:
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues and it is estimated to affect 2-8% of the population.

The management of pain, particularly chronic pain as common in patients with Fibromyalgia is a complex task and often does not have the desired success. In order to address this field, a Spanish medical research group working in a mayor hospital and specialized in the field of pain treatment has developed a new effective composition for the treatment of chronic pain.

The developed pharmaceutical composition comprises ketamine and pregabalin, acid analogues, aminobutyric arylcycloalkylamines and structurally related cyclidines.
The mode of administration of the drug was refined to an intravenous composition and was tested on a total of 36 patients. The outcome of this clinical test was positive with a significant pain decrease in the patients.

The research group is interested in licensing agreements for partners from the pharmaceutical industry
Advantages and Innovations:
- Composition and a combination therapy which decreases the side effects associated with other drug combinations used to treat pain.

- Effectiveness for the treatment of Fibromyalgia tested on hospital patients with satisfactory results
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applied in Spain and PCT

Partner sought

Type and Role of Partner Sought:
Type of partner sought: preferable pharmaceutical companies

- Specific area of activity of the partner: pharma research in the field of pain relieve and pain treatment

- Task to be performed by the partner sought: Licensees are sought to put the research into practice.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos